IRCT20161204031229N3
Recruiting
Phase 3
Study of the Efficacy of Teicoplanin on mortality rate of patients with COVID-19 Infection: A randomized clinical trial
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- COVID-19.
- Sponsor
- Iran University of Medical Sciences
- Enrollment
- 40
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Laboratory confirmed COVID\-19 with RT\-PCR
- •Laboratory confirmed COVID\-19 with lung CT scan
Exclusion Criteria
- •Chronic kidney Disease
- •Acute kidney injury
- •Breastfeeding
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
A comparison of therapeutic effects of teicoplanin versus vancomycin in patients admitted to the Intensive Care Unit after cardiac surgeryEndocarditis.Acute endocarditis, unspecifiedIRCT2016022220592N4Shahid Beheshti University of Medical Sciences46
Completed
Phase 2
Comparison between effects of Teicoplanin versus Vancomycin in treatment of catheter infection in hemodialysis patientshemodialysis patients who had catheter infection.Other infectious diseasesA00-B99IRCT138903234144N2Semnan university of medical sciences43
Terminated
Phase 4
Efficacy and Safety of Teicoplanin in CDADClostridium Difficile Infection-associated Diarrhea and ColitisNCT04003818Sanofi50
Recruiting
Not Applicable
Teicoplanin as Infection Prophylaxis in Pediatric Acute Myeloid Leukemia(Pediatric) Acute myeloid leukemiaNL-OMON29284Princess Máxima Center for Pediatric Oncology130
Completed
Phase 4
Teicoplanin Prophylaxis for Total Hip or Knee ArthroplastyTotal Hip and Knee ArthroplastiesNCT00719056University of Athens616